New funding for the UK biotech reflects growing interest in finding ways to remove dysfunctional proteins from the body.

In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.

Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players. 

After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.